株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

ブドウ膜炎 - 市場洞察、疫学、市場予測 2028年

Uveitis - Market Insights, Epidemiology, and Market Forecast - 2028

発行 DelveInsight Business Research LLP 商品コード 611055
出版日 ページ情報 英文 237 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.06円で換算しております。
Back to Top
ブドウ膜炎 - 市場洞察、疫学、市場予測 2028年 Uveitis - Market Insights, Epidemiology, and Market Forecast - 2028
出版日: 2019年09月01日 ページ情報: 英文 237 Pages
概要

主要7カ国(米国、英国、ドイツ、フランス、イタリア、スペイン、日本)のブドウ膜炎の有病数は、2017年に73万7,800人、その市場規模は約10億2,700万米ドルと推計されています。

当レポートでは、主要7カ国(米国、英国、ドイツ、フランス、イタリア、スペイン、日本)のブドウ膜炎市場を調査し、市場および疾患の概要、性別・年齢・タイプ・炎症グレード別の有病数、現行治療、アンメットニーズ、上市済み治療薬および新薬の概要、国別の市場規模、市場の成長要因および課題などを詳細にまとめています。

目次

第1章 重要洞察

第2章 ブドウ膜炎市場:概要

  • 市場シェアと分布状況(実績値)
  • 市場シェアと分布状況(予測値)

第3章 疾患の背景と概要:ブドウ膜炎

  • イントロダクション
  • 分類
  • 国際ブドウ膜炎研究グループ(IUSG)による臨床分類
  • SUNワーキンググループ
  • 症状
  • 病態生理
  • 病因
  • 診断
    • 米国家庭医学会(AAFP)

第4章 疫学と患者人口

  • 主な調査結果
  • 主要7カ国の有病数
  • 主要7カ国の診断有病数
  • 主要7カ国の診断数:タイプ別

第5章 米国のブドウ膜炎の疫学

  • 仮定と根拠
  • 総有病数
  • 診断有病数
  • 有病数:性別
  • 有病数:年齢別
  • 有病数:タイプ別
  • 非感染性ブドウ膜炎(NIU)の有病数:部位別
    • 非感染性前部ブドウ膜炎(aNIU)
    • 非感染性後部ブドウ膜炎(NUI-SP)
  • 非感染性前部ブドウ膜炎(aNIU)の有病数:炎症グレード別

第6章 欧州5カ国のブドウ膜炎の疫学

  • ドイツ
    • 仮定と根拠
    • 総有病数
    • 診断有病数
    • 有病数:性別
    • 有病数:年齢別
    • 有病数:タイプ別
    • 非感染性ブドウ膜炎(NIU)の有病数:部位別
    • 非感染性前部ブドウ膜炎(aNIU)の有病数:炎症グレード別
  • フランス
  • イタリア
  • スペイン
  • 英国

第7章 日本のブドウ膜炎の疫学

  • 仮定と根拠
  • 総有病数
  • 診断有病数
  • 有病数:性別
  • 有病数:年齢別
  • 有病数:タイプ別
  • 非感染性ブドウ膜炎(NIU)の有病数:部位別
  • 非感染性前部ブドウ膜炎(aNIU)の有病数:炎症グレード別

第8章 ブドウ膜炎の治療

  • 治療アルゴリズム
  • 第一選択薬:コルチコステロイド
  • 第二選択薬:免疫抑制剤
  • 第三選択薬:生物製剤
  • 非感染性ブドウ膜炎(NIU)に対する非コルチコステロイド全身免疫調節療法のガイダンス

第9章 アンメットニーズ

第10章 上市済み治療薬

  • キークロスコンペティション
  • Durezol:Sirion Therapeutics
    • 製品概要
    • 規制のマイルストーン
    • 長所と短所
    • 安全性と有効性
    • 製品プロファイル
  • Triesence:Novartis
  • Retisert:Valeant Pharmaceuticals International Inc
  • Ozurdex:Allergan plc
  • Humira:AbbVie Inc.
  • Yutiq:Eyepoint Pharmaceuticals
  • Tobradex:Alcon Laboratories
  • Acthar:Mallinckrodt
  • Iluvien:Alimera Sciences

第11章 新薬の分析

  • キークロスコンペティション
  • ADX-102:Aldeyra Therapeutics Inc.
    • 製品説明
    • 長所と短所
    • 臨床開発
    • 安全性と有効性
    • 製品プロファイル
  • シロリムス:参天製薬
  • EGP-437:EyeGate Pharmaceuticals
  • Suprachoroidal CLS-TA:Clearside Biomedical, Inc.
  • Sarilumab:Sanofi Aventis
  • LME636(OCS-02):Oculis Pharma
  • LFG316:Novartis
  • Abatacept(Orenica):Bristol-Myers Squibb Company
  • EYS606:Eyevensys

第12章 ブドウ膜炎:主要7カ国市場の分析

  • 主な調査結果
  • 主要7カ国の総市場規模
  • 主要7カ国の市場規模:治療薬別

第13章 米国:市場の見通し

  • 総市場規模
  • 市場規模:治療薬別

第14章 欧州5カ国:市場の見通し

  • ドイツの市場規模
    • 総市場規模
    • 市場規模:治療薬別
  • フランスの市場規模
    • 総市場規模
    • 市場規模:治療薬別
  • イタリアの市場規模
    • 総市場規模
    • 市場規模:治療薬別
  • スペインの市場規模
    • 総市場規模
    • 市場規模:治療薬別
  • 英国の市場規模
    • 総市場規模
    • 市場規模:治療薬別

第15章 日本:市場の見通し

  • 日本の市場規模
    • 総市場規模
    • 市場規模:治療薬別

第16章 市場の成長要因

第17章 市場の障壁

第18章 付録

第19章 調査手法

  • 参考資料

第20章 DelveInsightのサービス内容

第21章 免責事項

第22章 DelveInsightについて

図表

List of Tables

  • Table 1 IUSG Clinical Classification of Uveitis
  • Table 2 The SUN Working Group Anatomic Classification of Uveitis
  • Table 3 The SUN Working Group Descriptors of Uveitis
  • Table 4 The SUN Working Group Grading Scheme for Anterior Chamber Cells
  • Table 5 The SUN Working Group Grading Scheme for Anterior Chamber Cells
  • Table 6 KEY RECOMMENDATIONS FOR PRACTICE
  • Table 7 Region-Wise Prevalent Population of Uveitis (2017-2028)
  • Table 8 Diagnosed Prevalent Population of Uveitis (2017-2028)
  • Table 9 Type Specific Diagnosed Prevalent Population of Uveitis in the 7MM (2017-2028)
  • Table 10 Total Prevalent Population of Uveitis in US (2017-2028)
  • Table 11 Total Diagnosed Prevalent Population of Uveitis in US (2017-2028)
  • Table 12 Gender Specific Diagnosed Prevalent Population of Uveitis in the US (2017-2028)
  • Table 13 Age-Specific Diagnosed Prevalent Population of Uveitis in the US (2017-2028)
  • Table 14 Type-Specific Diagnosed Prevalent Population of Uveitis in US (2017-2028)
  • Table 15 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in the United States (2017-2028)
  • Table 16 Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in the United States (2017-2028)
  • Table 17 Prevalent Population of Uveitis in Germany (2017-2028)
  • Table 18 Diagnosed Prevalent Population of Uveitis in Germany (2017-2028)
  • Table 19 Gender Specific Diagnosed Prevalent Population of Uveitis in Germany (2017-2028)
  • Table 20 Age Specific Diagnosed Prevalent Population of Uveitis in Germany (2017-2028)
  • Table 21 Type Specific Diagnosed Prevalent Population of Uveitis in Germany (2017-2028)
  • Table 22 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in Germany (2017-2028)
  • Table 23 Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Germany (2017-2028)
  • Table 24 Prevalent Population of Uveitis in France (2017-2028)
  • Table 25 Diagnosed Prevalent Population of Uveitis in France (2017-2028)
  • Table 26 Gender Specific Diagnosed Prevalent Population of Uveitis in France (2017-2028)
  • Table 27 Age Specific Diagnosed Prevalent Population of Uveitis in France (2017-2028)
  • Table 28 Type Specific Diagnosed Prevalent Population of Uveitis in France (2017-2028)
  • Table 29 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in France (2017-2028)
  • Table 30 Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in France (2017-2028)
  • Table 31 Prevalent Population of Uveitis in Italy (2017-2028)
  • Table 32 Diagnosed Prevalent Population of Uveitis in Italy (2017-2028)
  • Table 33 Gender Specific Diagnosed Prevalent Population of Uveitis in Italy (2017-2028)
  • Table 34 Age Specific Diagnosed Prevalent Population of Uveitis in Italy (2017-2028)
  • Table 35 Type Specific Diagnosed Prevalent Population of Uveitis in Italy (2017-2028)
  • Table 36 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in Italy (2017-2028)
  • Table 37 Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Italy (2017-2028)
  • Table 38 Prevalent Population of Uveitis in Spain (2017-2028)
  • Table 39 Diagnosed Prevalent Population of Uveitis in Spain (2017-2028)
  • Table 40 Gender Specific Diagnosed Prevalent Population of Uveitis in Spain (2017-2028)
  • Table 41 Age Specific Diagnosed Prevalent Population of Uveitis in Spain (2017-2028)
  • Table 42 Type Specific Diagnosed Prevalent Population of Uveitis in Spain (2017-2028)
  • Table 43 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in Spain (2017-2028)
  • Table 44 Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Spain (2017-2028)
  • Table 45 Prevalent Population of Uveitis in UK (2017-2028)
  • Table 46 Diagnosed Prevalent Population of Uveitis in UK (2017-2028)
  • Table 47 Gender Specific Diagnosed Prevalent Population of Uveitis in UK (2017-2028)
  • Table 48 Age Specific Prevalent Population of Uveitis in UK (2017-2028)
  • Table 49 Type Specific Diagnosed Prevalent Population of Uveitis in UK (2017-2028)
  • Table 50 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in UK (2017-2028)
  • Table 51 Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in UK (2017-2028)
  • Table 52 Prevalent Population of Uveitis in Japan (2017-2028)
  • Table 53 Diagnosed Prevalent Population of Uveitis in Japan (2017-2028)
  • Table 54 Gender Specific Prevalent Population of Uveitis in Japan (2017-2028)
  • Table 55 Age Specific Prevalent Population of Uveitis in Japan (2017-2028)
  • Table 56 Type Specific Prevalent Population of Uveitis in Japan (2017-2028)
  • Table 57 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in Japan (2017-2028)
  • Table 58 Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Japan (2017-2028)
  • Table 59 First Line of Therapy of the treatment of Uveitis, 2019
  • Table 60 Marketed Drugs for Uveitis
  • Table 61 Tobradex, Clinical Trial Description, 2019
  • Table 62 Emerging Drugs Analysis
  • Table 63 ADX-102, Clinical Trial Description, 2019
  • Table 64 Sirolimus, Clinical Trial Description, 2019
  • Table 65 EGP 437, Clinical Trial Description, 2019
  • Table 66 Suprachoroidal CLS-TA, Clinical Trial Description, 2019
  • Table 67 Sarilumab, Clinical Trial Description, 2019
  • Table 68 LME636, Clinical Trial Description, 2019
  • Table 69 LFG316, Clinical Trial Description, 2019
  • Table 70 Abatacept, Clinical Trial Description, 2019
  • Table 71 EYS606, Clinical Trial Description, 2019
  • Table 72 Market size of Uveitis by Region in USD Million (2017-2028)
  • Table 73 Market Size of Uveitis by Therapies in the Seven Major Market (7MM),in USD Million (2017-2028)
  • Table 74 Market Size of Uveitis in the United States, USD Million (2017-2028)
  • Table 75 The United States Uveitis Market Size by Therapies in USD Million (2017-2028)
  • Table 76 Market Size of Uveitis in Germany, USD Million (2017-2028)
  • Table 77 Market Size of Uveitis by Therapies in Germany, in USD Million (2017-2028)
  • Table 78 Market Size of Uveitis in France, USD Million (2017-2028)
  • Table 79 Market Size of Uveitis by Therapies in France, in USD Million (2017-2028)
  • Table 80 Market Size of Uveitis in Italy, USD Million (2017-2028)
  • Table 81 Market Size of Uveitis by Therapies in Italy, in USD Million (2017-2028)
  • Table 82 Market Size of Uveitis in Spain, USD Million (2017-2028)
  • Table 83 Market Size of Uveitis by Therapies in Spain, in USD Million (2017-2028)
  • Table 84 Market Size of Uveitis in UK, USD Million (2017-2028)
  • Table 85 Market Size of Uveitis by Therapies in the United Kingdom, in USD Million (20172028)
  • Table 86 Market Size of Uveitis in Japan, USD Million (2017-2028)
  • Table 87 Market Size of Uveitis by Therapies in the Japan, in USD Million (2017-2028)

List of Figures

  • Figure 1 Structure of Eye
  • Figure 2 Types of Uveitis and Affected area
  • Figure 3 Classification of Uveitis
  • Figure 4 Types of Uveitis are based on the different parts of eye. Below are the four types
  • Figure 5 Symptoms of Uveitis
  • Figure 6 Pathogenetic mechanism of Uveitis
  • Figure 7 Mechanism of antigen processing and presentation.
  • Figure 8 Autoimmune conditions that cause uveitis
  • Figure 9 Causes of Uveitis
  • Figure 10 Diagnosis algorithm for Uveitis
  • Figure 11 Prevalent Population of Uveitis in the 7MM (2017-2028)
  • Figure 12 Diagnosed Prevalent Population of Uveitis in the 7MM (2017-2028)
  • Figure 13 Type Specific Diagnosed Prevalent Population of Uveitis in the 7MM (2017-2028)
  • Figure 14 Total Prevalent Population of Uveitis in United States (2017-2028)
  • Figure 15 Diagnosed Prevalent Population of Uveitis in United States (2017-2028)
  • Figure 16 Gender-Specific Diagnosed Prevalent Population of Uveitis in United States (2017-2028)
  • Figure 17 Age-Specific Diagnosed Prevalent Population of Uveitis in the United States (2017-2028)
  • Figure 18 Type Specific Diagnosed Prevalent Population of Uveitis in the US (2017-2028)
  • Figure 19 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in the United States (2017-2028)
  • Figure 20 Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in the United States (2017-2028)
  • Figure 21 Prevalent Population of Uveitis in Germany (2017-2028)
  • Figure 22 Diagnosed Prevalent Population of Uveitis in Germany (2017-2028)
  • Figure 23 Gender Specific Diagnosed Prevalent Population of Uveitis in Germany (2017-2028)
  • Figure 24 Age Specific Diagnosed Prevalent Population of Uveitis in Germany (2017-2028)
  • Figure 25 Type Specific Diagnosed Prevalent Population of Uveitis in Germany (2017-2028)
  • Figure 26 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in Germany (2017-2028)
  • Figure 27 Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Germany 2017-2028)
  • Figure 28 Prevalent Population of Uveitis in France (2017-2028)
  • Figure 29 Diagnosed Prevalent Population of Uveitis in France (2017-2028)
  • Figure 30 Gender Specific Diagnosed Prevalent Population of Uveitis in France (2017-2028)
  • Figure 31 Age Specific Diagnosed Prevalent Population of Uveitis in France (2017-2028)
  • Figure 32 Type Specific Diagnosed Prevalent Population of Uveitis in France (2017-2028)
  • Figure 33 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in France (2017-2028)
  • Figure 34 Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in France (2017-2028)
  • Figure 35 Prevalent Population of Uveitis in Italy (2017-2028)
  • Figure 36 Diagnosed Prevalent Population of Uveitis in Italy (2017-2028)
  • Figure 37 Gender Specific Diagnosed Prevalent Population of Uveitis in Italy (2017-2028)
  • Figure 38 Age Specific Diagnosed Prevalent Population of Uveitis in Italy (2017-2028)
  • Figure 39 Type Specific Diagnosed Prevalent Population of Uveitis in Italy (2017-2028)
  • Figure 40 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in Italy (2017-2028)
  • Figure 41 Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Italy (2017-2028)
  • Figure 42 Prevalent Population of Uveitis & Non-Infectious Uveitis (NIU) in Spain (2017-2028)
  • Figure 43 Diagnosed Prevalent Population of Uveitis in Spain (2017-2028)
  • Figure 44 Gender Specific Diagnosed Prevalent Population of Uveitis in Spain (2017-2028)
  • Figure 45 Age Specific Diagnosed Prevalent Population of Uveitis in Spain (2017-2028)
  • Figure 46 Type Specific Diagnosed Prevalent Population of Uveitis in Spain (2017-2028)
  • Figure 47 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in Spain (2017-2028)
  • Figure 48 Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Spain (2017-2028)
  • Figure 49 Prevalent Population of Uveitis in UK (2017-2028)
  • Figure 50 Diagnosed Prevalent Population of Uveitis in UK (2017-2028)
  • Figure 51 Gender Specific Diagnosed Prevalent Population of Uveitis in UK (2017-2028)
  • Figure 52 Age Specific Diagnosed Prevalent Population of Uveitis in UK (2017-2028)
  • Figure 53 Type Specific Diagnosed Prevalent Population of Uveitis in the UK (2017-2028)
  • Figure 54 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in the UK (2017-2028)
  • Figure 55 Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in the UK (2017-2028)
  • Figure 56 Prevalent Population of Uveitis in Japan (2017-2028)
  • Figure 57 Diagnosed Prevalent Population of Uveitis in Japan (2017-2028)
  • Figure 58 Gender Specific Prevalent Population of Uveitis in Japan (2017-2028)
  • Figure 59 Age Specific Prevalent Population of Uveitis in JAPAN (2017-2028)
  • Figure 60 Type Specific Prevalent Population of Uveitis in JAPAN (2017-2028)
  • Figure 61 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in Japan (2017-2028)
  • Figure 62 Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Japan (2017-2028)
  • Figure 63 Treatment Regimens
  • Figure 64 Treatment Algorithm of Uveitis
  • Figure 65 Therapeutic algorithm in endogenous Anterior Uveitis (AU)
  • Figure 66 Therapeutic algorithm in endogenous Intermediate Uveitis (IU)
  • Figure 67 Therapeutic algorithm in immune-mediated posterior uveitis or panuveiti
  • Figure 68 Management flowchart for non-infectious uveitis
  • Figure 69 Unmet Needs
  • Figure 70 Market size of Uveitis by Region in USD Million (2017-2028)
  • Figure 71 Market Size of Uveitis by Therapies in the Seven Major Market (7MM), in USD Million (2017-2028)
  • Figure 72 Market Size of Uveitis in the United States, USD Million (2017-2028)
  • Figure 73 The United States Uveitis Market Size by Therapies in USD Million (2017-2028)
  • Figure 74 Market Size of Uveitis in Germany, USD Million (2017-2028)
  • Figure 75 Market Size of Uveitis by Therapies in Germany, in USD Million (2017-2028)
  • Figure 76 Market Size of Uveitis in France, USD Million (2017-2028)
  • Figure 77 France Uveitis Market Size by Therapies in USD Million (2017-2028)
  • Figure 78 Market Size of Uveitis in Italy, USD Million (2017-2028)
  • Figure 79 Italy Uveitis Market Size by Therapies in USD Million (2017-2028)
  • Figure 80 Market Size of Uveitis in Spain, USD Million (2017-2028)
  • Figure 81 Spain Uveitis Market Size by Therapies in USD Million (2017-2028)
  • Figure 82 Market Size of Uveitis in United Kingdom, USD Million (2017-2028)
  • Figure 83 United Kingdom Uveitis Market Size by Therapies in USD Million (2017-2028)
  • Figure 84 Market Size of Uveitis in Japan, USD Million (2017-2028)
  • Figure 85 Japan Uveitis Market Size by Therapies in USD Million (2017-2028)
  • Figure 86 Market Drivers of Uveitis
  • Figure 87 Market Barriers of Uveitis
目次
Product Code: DIMI0072

DelveInsight's 'Uveitis- Market Insights, Epidemiology, and Market Forecast-2028' report deliver an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Uveitis in the United States, EU5 (Germany, Spain, Italy, France and the United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of Uveitis from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2028

Uveitis - Disease Understanding and Treatment Algorithm

The DelveInsight Uveitis market report gives a thorough understanding of the Uveitis by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Uveitis in the US, Europe, and Japan.

Uveitis

The Uveitis epidemiology division provide insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Prevalence of Uveitis in 7MM, Total Diagnosed Prevalence of Uveitis in 7MM, Gender-specific Diagnosed Prevalence of Uveitis, Age-specific Diagnosed Prevalence of Uveitis, Type Specific Diagnosed Prevalence of Uveitis, Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location, and Grade-specific Diagnosed Prevalence of Uveitis) scenario of Uveitis in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.

According to DelveInsight, the total number of diagnosed prevalent population of Uveitis in 7MM was found to be approximately 737,800 in the year 2017.

Uveitis Drug Chapters

This segment of the Uveitis report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

The current management of uveitis solely depends on corticosteroids, immunosuppressants, and biologics. Corticosteroids are recommended as first-line of therapies for the treatment of uveitis. The approved and upcoming therapies that fall under this category includes Iluvien, EGP-437, and Suprachoroidal CLS-TA. Corticosteroids accounts for the 65.44% of the total Uveitis market in 2017. Immunosuppressants are the second-line of treatment therapy. The appropriate treatment and choice of immunosuppressive therapy of Uveitis depend on both the extent and severity of the inflammatory process. Biologic response modifiers, or so-called biologics, are the relatively new medications studied and used for the treatment of noninfectious uveitis and other ocular inflammatory diseases. Biologic therapy can be an alternative in patients with inadequate response to or tolerance of conventional immunotherapy.

The horizon currently appears very bright, given the many therapeutic agents and approaches for uveitis and ocular inflammatory diseases. Different classes of agents, from calcineurin inhibitors to mTOR inhibitors and IL inhibitors, among others, are being evaluated. In addition, delivery systems such as iontophoresis will also allow novel methods of safe and effective administration of pharmacologic agents. Hopefully, such efforts will lead to therapeutic options for our patients in the near future.

Launch of emerging therapies, such as Sirolimus (for Non-Infectious Uveitis of the Posterior Segment (NIU-PS)), EGP-437 (for Non-Infectious Anterior Uveitis), Sarilumab (for Non-Infectious, Intermediate, Posterior or Pan-Uveitis (NIU)), Suprachoroidal CLS-TA(Triamcinolone Acetonide) (for Macular edema associated with non-infectious uveitis), LFG316 (Non-infectious Intermediate Uveitis; Non-infectious Posterior Uveitis; Non-infectious Panuveitis), LME636 ( Anterior Acute Uveitis) shall further create a positive impact on the market.

Apart from the pharmacological therapies few companies are working in the development of gene therapy which can provide a cure to the disease.

Uveitis Market Outlook

The Uveitis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Uveitis in 7MM was found to be approximately USD 1027.0 million in 2017 and is expected to increase from 2017-2028.

Uveitis Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Uveitis Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Uveitis Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Uveitis Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Uveitis Infections market
  • Organize sales and marketing efforts by identifying the best opportunities for Uveitis market
  • To understand the future market competition in the Uveitis market.

Table of Contents

1. Key Insight

2. Uveitis Market Overview at a Glance

  • 2.1. Market Share (%) Distribution of Uveitis in 2017
  • 2.2. Market Share (%) Distribution of Uveitis in 2028

3. Disease Background and Overview: Uveitis

  • 3.1. Introduction
  • 3.2. Classification of Uveitis
  • 3.3. International Uveitis Study Group (IUSG) Clinical Classification of Uveitis
  • 3.4. The Standardization of Uveitis Nomenclature (SUN) Working Group
  • 3.5. Symptoms of Uveitis
  • 3.6. Pathophysiology
  • 3.7. Etiology of Uveitis
  • 3.8. Diagnosis of Uveitis
    • 3.8.1. American Academy of Family Physicians

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. Prevalent Population of Uveitis in the 7MM
  • 4.3. Diagnosed Prevalent Population of Uveitis in the 7MM
  • 4.4. Type Specific Diagnosed Prevalent Population of Uveitis in the 7MM

5. United States-Epidemiology of Uveitis

  • 5.1. Assumptions and Rationale
  • 5.2. Total Prevalent Population of Uveitis in the United States
  • 5.3. Diagnosed Prevalent Population of Uveitis in the United States
  • 5.4. Gender-Specific Diagnosed Prevalent Population of Uveitis in United States
  • 5.5. Age-Specific Diagnosed Prevalent Population of Uveitis in United States
  • 5.6. Type Specific Diagnosed Prevalent Population of Uveitis in United States
  • 5.7. Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location
    • 5.7.1. Diagnosed prevalent cases of Anterior noninfectious Uveitis (aNIU) in the United States
    • 5.7.2. Diagnosed prevalent cases of Nonanterior NIU (Posterior Segment) or NIPU in the United States
  • 5.8. Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in the United States

6. EU-5 Epidemiology of Uveitis

  • 6.1. Germany
    • 6.1.1. Assumptions and Rationale
    • 6.1.2. Prevalent Population of Uveitis in Germany
    • 6.1.3. Diagnosed Prevalent Population of Uveitis in Germany
    • 6.1.4. Gender Specific Diagnosed Prevalence of Uveitis in Germany
    • 6.1.5. Age Group Specific Diagnosed Prevalence of Uveitis in Germany
    • 6.1.6. Type Specific Diagnosed Prevalence of Uveitis in Germany
    • 6.1.7. Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location
    • 6.1.8. Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Germany
  • 6.2. France
    • 6.2.1. Assumptions and Rationale
    • 6.2.2. Prevalent Population of Uveitis in France
    • 6.2.3. Diagnosed Prevalent Population of Uveitis in France
    • 6.2.4. Gender Specific Diagnosed Prevalence of Uveitis in France
    • 6.2.5. Age Specific Diagnosed Prevalence of Uveitis in France
    • 6.2.6. Type Specific Diagnosed Prevalence of Uveitis in France
    • 6.2.7. Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location
    • 6.2.8. Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in France
  • 6.3. Italy
    • 6.3.1. Assumptions and Rationale
    • 6.3.2. Prevalent Population of Uveitis in the Italy
    • 6.3.3. Diagnosed Prevalent Population of Uveitis in Italy
    • 6.3.4. Gender Specific Diagnosed Prevalence of Uveitis in Italy
    • 6.3.5. Age Specific Diagnosed Prevalence of Uveitis in Italy
    • 6.3.6. Type Specific Diagnosed Prevalence of Uveitis in Italy
    • 6.3.7. Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location
    • 6.3.8. Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Italy
  • 6.4. Spain
    • 6.4.1. Assumptions and Rationale
    • 6.4.2. Prevalent Population of Uveitis in the Spain
    • 6.4.3. Diagnosed Prevalent Population of Uveitis in Spain
    • 6.4.4. Gender Specific Diagnosed Prevalence population of Uveitis in Spain
    • 6.4.5. Age Specific Diagnosed Prevalence of Uveitis in Spain
    • 6.4.6. Type Specific Diagnosed Prevalence of Uveitis in Spain
    • 6.4.7. Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in Spain
    • 6.4.8. Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Spain
  • 6.5. United Kingdom
    • 6.5.1. Assumptions and Rationale
    • 6.5.2. Prevalent Population of Uveitis in the UK
    • 6.5.3. Diagnosed Prevalent Population of Uveitis in United Kingdom
    • 6.5.4. Gender Specific Diagnosed Prevalence of Uveitis in UK
    • 6.5.5. Age Specific Diagnosed Prevalence of Uveitis in UK
    • 6.5.6. Type Specific Diagnosed Prevalence of Uveitis in UK
    • 6.5.7. Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in the UK
    • 6.5.8. Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in the UK

7. Japan

  • 7.1. Assumptions and Rationale
  • 7.2. Prevalent Population of Uveitis in the Japan
  • 7.3. Diagnosed Prevalent Population of Uveitis in the Japan
  • 7.4. Gender Specific Prevalence of Uveitis in Japan
  • 7.5. Age Specific Prevalence of Uveitis in Japan
  • 7.6. Type Specific Prevalence of Uveitis in Japan
  • 7.7. Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in Japan
  • 7.8. Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Japan

8. Treatment of Uveitis

  • 8.1. Treatment Algorithm
  • 8.2. First Line of Therapy: Corticosteroids
  • 8.3. Second Line of Therapy: Immunosuppressants
  • 8.4. Third Line of Therapy: Biologics
  • 8.5. Guidance on Non-corticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis: Fundamentals of Care for Uveitis (FOCUS) Initiative

9. Unmet Needs

10. Marketed Drugs

  • 10.1. Key Cross Competition
  • 10.2. Durezol: Sirion Therapeutics
    • 10.2.1. Product Description
    • 10.2.2. Regulatory Milestones
    • 10.2.3. Advantages & Disadvantages
    • 10.2.4. Safety and Efficacy
    • 10.2.5. Product Profile
  • 10.3. Triesence: Novartis
    • 10.3.1. Drug Description
    • 10.3.2. Regulatory Milestones
    • 10.3.3. Advantages & Disadvantages
    • 10.3.4. Safety and Efficacy
    • 10.3.5. Product Profile
  • 10.4. Retisert: Valeant Pharmaceuticals International Inc
    • 10.4.1. Drug Description
    • 10.4.2. Regulatory Milestones
    • 10.4.3. Advantages & Disadvantages
    • 10.4.4. Safety
    • 10.4.5. Efficacy
    • 10.4.6. Product Profile
  • 10.5. Ozurdex: Allergan plc
    • 10.5.1. Drug Description
    • 10.5.2. Regulatory Milestones
    • 10.5.3. Advantages & Disadvantages
    • 10.5.4. Efficacy
    • 10.5.5. Safety
    • 10.5.6. Product Profile
  • 10.6. Humira: AbbVie Inc.
    • 10.6.1. Drug Description
    • 10.6.2. Regulatory Milestones
    • 10.6.3. Advantages & Disadvantages
    • 10.6.4. Safety and Efficay
    • 10.6.5. Product Profile
  • 10.7. Yutiq: Eyepoint Pharmaceuticals
    • 10.7.1. Product Description
    • 10.7.2. Clinical Development
    • 10.7.3. Advantages & Disadvantages
    • 10.7.4. Safety and Efficacy
    • 10.7.5. Product Profile
  • 10.8. Tobradex: Alcon Laboratories
    • 10.8.1. Product Description
    • 10.8.2. Other Developmental Activities
    • 10.8.3. Product Profile
  • 10.9. Acthar: Mallinckrodt
    • 10.9.1. Product Description
    • 10.9.2. Other Developmental Activities
    • 10.9.3. Advantages and Disadvantages
    • 10.9.4. Safety and Efficacy
    • 10.9.5. Product Profile
  • 10.10. Iluvien: Alimera Sciences
    • 10.10.1. Product Description
    • 10.10.2. Other Developmental Activities
    • 10.10.3. Clinical Development
    • 10.10.4. Clinical Trials Information
    • 10.10.5. Safety and Efficacy
    • 10.10.6. Product Profile

11. Emerging Drugs Analysis

  • 11.1. Key Cross Competition
  • 11.2. ADX-102: Aldeyra Therapeutics Inc.
    • 11.2.1. Product Description
    • 11.2.2. Advantages & Disadvantages
    • 11.2.3. Clinical Development
    • 11.2.4. Safety and Efficacy
    • 11.2.5. Product Profile
  • 11.3. Sirolimus: Santen
    • 11.3.1. Product Description
    • 11.3.2. Regulatory Milestones
    • 11.3.3. Advantages & Disadvantages
    • 11.3.4. Clinical Development
    • 11.3.5. Safety and Efficacy
    • 11.3.6. Product Profile
  • 11.4. EGP-437: EyeGate Pharmaceuticals
    • 11.4.1. Product Description
    • 11.4.2. Regulatory Milestones
    • 11.4.3. Advantages & Disadvantages
    • 11.4.4. Clinical Development
    • 11.4.5. Safety and Efficacy
    • 11.4.6. Product Profile
  • 11.5. Suprachoroidal CLS-TA: Clearside Biomedical, Inc.
    • 11.5.1. Product Description
    • 11.5.2. Clinical Development
    • 11.5.3. Safety and Efficacy
    • 11.5.4. Product Profile
  • 11.6. Sarilumab: Sanofi Aventis
    • 11.6.1. Product Description
    • 11.6.2. Product Development Activities
    • 11.6.3. Advantages and Disadvantages
    • 11.6.4. Clinical Development
    • 11.6.5. Safety and Efficacy
    • 11.6.6. Product Profile
  • 11.7. LME636 (OCS-02): Oculis Pharma
    • 11.7.1. Product Description
    • 11.7.2. Other development activities
    • 11.7.3. Clinical Development
    • 11.7.4. Safety and Efficacy
    • 11.7.5. Product Profile
  • 11.8. LFG316: Novartis
    • 11.8.1. Product Description
    • 11.8.2. Other development activities
    • 11.8.3. Clinical Development
    • 11.8.4. Safety and Efficacy
    • 11.8.5. Product Profile
  • 11.9. Abatacept (Orenica): Bristol-Myers Squibb Company
    • 11.9.1. Product Description
    • 11.9.2. Clinical Development
    • 11.9.3. Safety and Efficacy
    • 11.9.4. Product Profile
  • 11.10. EYS606: Eyevensys
    • 11.10.1. Product Description
    • 11.10.2. Other development activities
    • 11.10.3. Clinical Development
    • 11.10.4. Safety and Efficacy
    • 11.10.5. Product Profile

12. Uveitis: 7 Major Market Analysis

  • 12.1. Key Findings
  • 12.2. Market Size of Uveitis in the 7MM
  • 12.3. Market Size of Uveitis by Therapies in the 7MM

13. United States: Market Outlook

  • 13.1. Total Market size of Uveitis
  • 13.2. Uveitis Market Size by Therapies

14. EU5: Market Outlook

  • 14.1. Germany Market Size
    • 14.1.1. Total Market size of Uveitis
    • 14.1.2. Uveitis Market Size by Therapies
  • 14.2. France Market Size
    • 14.2.1. Total Market size of Uveitis
    • 14.2.2. Uveitis Market Size by Therapies
  • 14.3. Italy Market Size
    • 14.3.1. Total Market size of Uveitis
    • 14.3.2. Uveitis Market Size by Therapies
  • 14.4. Spain Market Size
    • 14.4.1. Total Market size of Uveitis
    • 14.4.2. Uveitis Market Size by Therapies
  • 14.5. United Kingdom Market Size
    • 14.5.1. Total Market size of Uveitis
    • 14.5.2. Uveitis Market Size by Therapies

15. Japan: Market Outlook

  • 15.1. Japan: Market Size
    • 15.1.1. Total Market size of Uveitis
    • 15.1.2. Uveitis Market Size by Therapies

16. Market Drivers

17. Market Barriers

18. Appendix

19. Report Methodology

  • 19.1. Sources Used

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight

Back to Top